NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP
Iridex Corp. IRIX
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$52.7M
▲ 8.2% vs FY2024
EPS · FY25
$-0.26
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-126.4%
Net margin · FY25
-8.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 52.7M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 8 cents on every revenue dollar this year.
Per share
USD -0.26
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-126.4%
Return on equity, FY2025
ROE
Operating margin-4.9%
Net margin-8.4%
Return on assets-15.2%
Each USD of equity lost 126 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+7.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.6%
+7.7%
+2.3%
+3.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+24.5%
Change, 10 years+72.9%
The share count grew 25% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 29.2M
total assets, end of FY2025
Total assetsUSD 29.2M
EquityUSD 4.9M
CashUSD 6.0M
Current ratio1.91×
Equity funds 17% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.0
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−0.26
−0.54
−0.59
−0.47
−0.34
−0.46
−0.64
−1.05
−1.11
−1.15
0.05
0.97
0.22
0.16
0.26
0.30
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−126.4
−153.4
−71.5
−37.2
−25.7
−31.6
−33.5
−42.4
−36.9
−32.2
1.4
33.7
9.3
6.5
12.5
17.7
17.2
Shares out B
0.02
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
65 of 65
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed